Intravenous Ferric Carboxymaltose for Improvement of Metabolic Parameters and Vascular Function in T2DM-patients With Iron Deficiency

Trial Profile

Intravenous Ferric Carboxymaltose for Improvement of Metabolic Parameters and Vascular Function in T2DM-patients With Iron Deficiency

Recruiting
Phase of Trial: Phase III

Latest Information Update: 15 Dec 2016

At a glance

  • Drugs Ferric carboxymaltose (Primary)
  • Indications Iron deficiency anaemia; Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms CLEVER
  • Sponsors GWT-TUD GmbH
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 12 Dec 2016 Planned End Date changed from 1 Mar 2017 to 1 Mar 2018.
    • 12 Dec 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top